Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03712813
Recruitment Status : Recruiting
First Posted : October 19, 2018
Last Update Posted : December 9, 2019
Sponsor:
Information provided by (Responsible Party):
Tarah J Ballinger, MD, Indiana University

Brief Summary:
The purpose of this study is to compare the effect of low intensity vibration (LIV) delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer planned to initiate aromatase inhibitor therapy who do not currently participate in regular exercise, compared to a wait- listed control.

Condition or disease Intervention/treatment Phase
Breast Cancer Device: Macrodyne LivMD plate Phase 2

Detailed Description:

This is a randomized phase II, two arm, single-center study designed to compare the effect of LIV versus wait-list control on the clinical parameter of energetic capacity, or power generation, in patients with early stage breast cancer receiving aromatase inhibitor therapy over a 12-month period. The primary endpoint is the 12-month change in energetic capacity since baseline.

Primary Objective To compare the effect of LIV delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer planned to initiate aromatase inhibitor therapy who do not currently participate in regular exercise, compared to a wait- listed control

Secondary Objectives

  1. To compare the effect of LIV versus wait-listed control upon muscle contractile properties including peak power, fatigue resistance, and recovery, measured by isokinetic knee extension
  2. To compare the effect of LIV versus wait- listed control upon body composition (lean mass, total adiposity) measured by DXA scan
  3. To compare the effect of LIV versus wait- listed control upon bone mineral density (T score) measured by DXA scan
  4. To compare the effect of LIV versus wait- listed control upon muscle adipose infiltration measured by muscle density on peripheral quantitative CT imaging of the proximal and distal tibia and radius
  5. To compare the effect of LIV versus wait-listed control on trabecular and cortical volumetric bone mineral density by high resolution peripheral quantitative CT of the distal and diaphyseal tibia and radius
  6. To compare the effect of LIV versus wait- listed control on serologic markers of bone turnover, including TGF-beta and NTX
  7. To compare the effect of LIV versus wait- listed controls upon patient reported outcome measures of fatigue (measured by the Basic Fatigue Inventory), muscle ache, and joint pain (measured by PRO-CTCAE)
  8. To describe the feasibility of LIV in this patient population, defined by patient compliance and follow up with the intervention

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Patients will be randomized in a 1:1 ratio to LIV or the standard of care. The total patient enrollment will be 72 patients with 36 patients in each arm. Upon registration, subjects will be randomized and given an automated sequence number.
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
Actual Study Start Date : September 16, 2019
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Macrodyne LivMD plate Device: Macrodyne LivMD plate
Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.

No Intervention: Wait-Listed Control



Primary Outcome Measures :
  1. Mean change in energetic capacity measured by peak power generation on a stationary bicycle [ Time Frame: Baseline and 12 months ]
    Peak power will be measured using the Power Protocol-B


Secondary Outcome Measures :
  1. Change in muscle contractile properties including peak power, fatigue resistance, and time to recovery measured by isokinetic knee extension [ Time Frame: Baseline and 12 months ]
    A Biodex 4 system will be used to measure each subject's muscle contractile properties

  2. Change in lean body mass by DEXA scan [ Time Frame: Baseline and 12 months ]
  3. Change in bone mineral density of the lumbar spine by T score measured by DXA scan [ Time Frame: Baseline and 12 months ]
  4. Change in trabecular and cortical volumetric bone mineral density measured by high resolution peripheral quantitative CT [ Time Frame: Baseline and 12 months ]
  5. Change in serologic bone markers of bone turnover (TGF-beta and NTX) by quantitative measurements using ELISA [ Time Frame: Baseline and 12 months ]
  6. Patient reported fatigue measured by the Basic Fatigue Inventory score [ Time Frame: Baseline and 12 months ]
    Average of all 9 items ranging in a score of 0-10 (total possible score of 11) scores range from 1( no fatigue/does not interfere) to 10 (as bad as you can imagine/completely interferes)

  7. Patient reported aching muscles and joint pain measured by NCI Patient Reported Outcomes-Common Terminology Criteria for Adverse Events score [ Time Frame: Baseline and 12 months ]
    Average of 2 scale items for aching muscles and joint pain on a 5-point Likert scale (ranging in severity) with a total possible score of 5 (i.e. very severe/ almost constantly)

  8. Feasibility of low intensity vibration defined by patient compliance [ Time Frame: Baseline and 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years
  2. Diagnosis of DCIS or stage I, II, or III breast cancer 3 Planned to initiate an AI

    1. Post- menopausal defined as ≥ 60 years of age, prior bilateral oophorectomy, or age over 50 and absence of any menstrual periods in the last 12 months, or FSH and estradiol in the menopausal range
    2. Premenopausal patients receiving chemical ovarian suppression are allowed
    3. Prior aromatase inhibitor use (if this is a second primary, for example) is allowed as long as it has been more than 12 months
    4. Prior tamoxifen is allowed if switching to an aromatase inhibitor, as long as it has been 28 days between last tamoxifen dose and the baseline procedures (per the half-life of tamoxifen)

4. Completion of all primary therapy for breast cancer, including surgery, radiation, and chemotherapy. Patients must be ≥ 21 days from chemotherapy completion and ≥14 days from radiation completion. Ongoing HER2 targeted therapy with trastuzumab or pertuzumab, or TDM1 is allowed. Neratinib, immunotherapy, or CDK4/6 inhibitor therapy is not allowed.

5. Baseline T score > - 2.5 on DXA 6. Body weight less than 275 lbs., as dictated by the weight limit for the LIV platforms 7. ECOG performance status of 0-2 at the time of study enrollment 8. Informed consent and authorization of the release of health information must be obtained according to institutional guidelines 9. Physically able to stand unassisted for 10 minutes at a time 10. Currently not participating in regular exercise (defined as less than 90 minutes of moderate to vigorous exercise per week measured by the RPAQ questionnaire)

Exclusion Criteria:

  1. Unwilling to co-enroll onto the companion FIT core study (IRB study #1707550885)
  2. Diagnosis of other disorder affecting bone function or turnover, such as Paget's disease, renal osteodystrophy, parathyroid disorders, vitamin D deficiency/osteomalacia, chronic renal disease (Cr > 1.4)

    a. Vitamin D will be checked during screening. Patients with Vit D < 20 can be enrolled if supplementation is initiated per the treating physician.

  3. Prior history of non-traumatic, fragility bone fracture
  4. Any muscle or neuromuscular disorder affecting muscle function, such as muscular dystrophy, myositis, or amyotrophic lateral sclerosis
  5. Use of bisphosphonates or denosumab within the prior 12 months
  6. History of retinal detachment
  7. Current or planned pacemaker
  8. Current or planned cochlear implant
  9. Any condition precluding power protocol participation (i.e. riding a stationary bicycle), including: NYHA class III or IV congestive heart failure, uncontrolled angina, myocardial infarction in the prior 12 months, orthopedic surgery in the previous 6 months or plans for orthopedic surgery during the study period, chronic uncontrolled pulmonary conditions such as uncontrolled asthma (symptoms > 2 days/week) or dyspnea requiring oxygen, symptomatic peripheral vascular disease, or any other comorbidity that would interfere with the ability to complete and comply with the protocol in the opinion of the investigator
  10. Metastatic breast cancer

    a. History of prior treated malignancies, other than breast cancer, that are now stable, are in remission, and do not require active therapy, are acceptable.

  11. Patients requiring chronic anticoagulation are excluded from participation in the optional muscle biopsy collection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03712813


Contacts
Layout table for location contacts
Contact: Jessica L Sollars, RN 317-278-5117 jlsherma@iupui.edu
Contact: Tarah Ballinger, MD tarab@iu.edu

Locations
Layout table for location information
United States, Indiana
Indiana University Melvin & Bren Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Jessica Sollars    317-278-5117    jlsherma@iupui.edu   
Sponsors and Collaborators
Indiana University
Investigators
Layout table for investigator information
Principal Investigator: tarah Ballinger, MD Indiana University

Layout table for additonal information
Responsible Party: Tarah J Ballinger, MD, Assistant Professor of Clinical Medicine, Indiana University
ClinicalTrials.gov Identifier: NCT03712813    
Other Study ID Numbers: IUSCC-0680
First Posted: October 19, 2018    Key Record Dates
Last Update Posted: December 9, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Keywords provided by Tarah J Ballinger, MD, Indiana University:
aromatase inhibitors
low intensity vibration
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs